Skip to main content

David Sinclaire Van Mater

Assistant Professor of Pediatrics
Pediatrics, Hematology-Oncology
102382, Durham, NC 27710
Dept of Pediatrics, Box 2916, Durham, NC 27710

Selected Grants


MAIN STUDY: Developing Evidence-Based Crieteria for Initiating Treatment fo NF1-OPG.

Clinical TrialPrincipal Investigator · Awarded by Children's Tumor Foundation · 2015 - 2025

Genome Editing for the Treatment of Neurofibromatosis Type I

ResearchCollaborator · Awarded by Gilbert Family Foundation · 2022 - 2024

Exploring the Use of Gene Therapies to Treat Neurofibromatosis Type I

FellowshipMentor · Awarded by National Institutes of Health · 2022 - 2024

MAIN STUDY: Developing Evidence-Based Crieteria for Initiating Treatment fo NF1-OPG.

Clinical TrialPrincipal Investigator · Awarded by Children's Tumor Foundation · 2015 - 2025

Genome Editing for the Treatment of Neurofibromatosis Type I

ResearchCollaborator · Awarded by Gilbert Family Foundation · 2022 - 2024

Exploring the Use of Gene Therapies to Treat Neurofibromatosis Type I

FellowshipMentor · Awarded by National Institutes of Health · 2022 - 2024

Targeting epigenetic dysregulation in pediatric cancer

ResearchCo Investigator · Awarded by Dana-Farber Cancer Institute · 2019 - 2023

Visual Field Outcomes in Pediatric Patients with NF1-associated Optic Pathway Gliomas

ResearchPrincipal Investigator · Awarded by Boston Children's Hospital · 2018 - 2019

Expansion of the AYA Oncology Initiative at Duke University

ResearchPrincipal Investigator · Awarded by St. Baldrick's Foundation · 2016 - 2018

Dissecting the role of injury is sarcoma formation

ResearchPrincipal Investigator · Awarded by Sarcoma Alliance for Research Through Collaboration · 2015 - 2017

Dissecting the role of injury is sarcoma formation

ResearchPrincipal Investigator · Awarded by Sarcoma Alliance for Research Through Collaboration · 2015 - 2017

External Relationships


  • Alexion Pharmaceuticals, Inc. a subsidiary of AstraZeneca

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.